Profile photo

Nuclear Medicine and Theranostics With Jeremie Calais, MD, MSc

Oncology / Hematology

Dr. Calais is a nuclear medicine physician who specializes in cancer imaging and theranostics. He is an associate professor at the David Geffen School of Medicine, director of the UCLA Theranostics Program, and director of the Clinical Research Program of the Ahmanson Translational Theranostics Division. He conducts investigator-initiated and industry-sponsored clinical trials of targeted molecular imaging and radio nuclide therapy.

LuPSMA Response and Lutetium-177 Delivery at SUO 2024

Dear readers,

Today, I would like to highlight two hot topics discussed at the 25th annual meeting of the SUO.

First, Mohamed Ahmad, MB, BCh, presented on “Survival Patters Among Clinically Node Positive Prostate Cancer Treated with Radical Prostatectomy.” He further evaluated the response of mCRPC by site-specific disease to 177Lu-PSMA-617.

Another topic of discussion focused on 177Lu-TLX591 plus the standard of care compared to the standard of care alone in patients with mCRPC.

Warmly,
Dr. Jeremie Calais

Articles
  • Mashup Score: 6
    • Profile photo of MayoUrology
      MayoUrology

      Today at #SUO24, “Evaluation of Response to 177Lu-PSMA-617 by Site Specific Disease in Metastatic Castrate-Resistant Prostate Cancer”, presented by @Moh_AhmedMD.

      The second of four presentations at 9am today in Dallas! #ProstateCancer https://t.co/EB1guCEP6Q https://t.co/zAjyjx5TWY

      Read the original tweet here

    Tweet Tweets with this article